Investors have high hopes for the $2.7 billion gene editing pioneer, yet there are reasons for both optimism and pessimism.
News & Analysis: CRISPR Therapeutics
The gene-editing approach might prove more useful outside the clinic.
CRISPR Therapeutics and Curaleaf Holdings could have a lot more room to run.
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
The richest gene-editing company just got a whole lot richer.
First-quarter earnings results from three gene-editing companies gave Wall Street analysts pause.
CRISPR and partner Vertex bagged an important regulatory designation for CTX001 last month.
Which stock wins in a match-up between these two CRISPR gene-editing pioneers?
Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.